IGM Biosciences to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day

MOUNTAIN VIEW, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day on February 12, 2021 at… Continue reading IGM Biosciences to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day

IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant

– IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors – MOUNTAIN VIEW, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS) today announced that it has entered into an exclusive license agreement with Medivir AB (Nasdaq Stockholm: MVIR), through which IGM will receive global, exclusive development… Continue reading IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant

IGM Announces Closing of $230 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

MOUNTAIN VIEW, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the closing of its upsized underwritten public offering of 1,221,224 shares of its common stock, which includes the exercise of the underwriters’ option to purchase additional shares in full, and pre-funded warrants to purchase 1,334,332 shares of its… Continue reading IGM Announces Closing of $230 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

IGM Announces Closing of $230 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

MOUNTAIN VIEW, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the closing of its upsized underwritten public offering of 1,221,224 shares of its common stock, which includes the exercise of the underwriters’ option to purchase additional shares in full, and pre-funded warrants to purchase 1,334,332 shares of its… Continue reading IGM Announces Closing of $230 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

IGM Announces Pricing of Upsized $200 million Public Offering

MOUNTAIN VIEW, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the pricing of its upsized underwritten public offering of shares of its common stock at a price to the public of $90.00 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase shares… Continue reading IGM Announces Pricing of Upsized $200 million Public Offering

IGM Announces Proposed Public Offering

MOUNTAIN VIEW, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $150 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common stock, in an underwritten public… Continue reading IGM Announces Proposed Public Offering

IGM Biosciences Presents First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting

– 9 of 14 Patients Showed Reduction in Tumor Size, Including Two Recently Reported Complete Responses – – Company to Host Conference Call and Webcast Today at 2:00 p.m. ET – MOUNTAIN VIEW, Calif., Dec. 05, 2020 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered… Continue reading IGM Biosciences Presents First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting

IGM Biosciences to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

MOUNTAIN VIEW, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, has participated in a fireside chat in advance of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3,… Continue reading IGM Biosciences to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

IGM Biosciences Announces Third Quarter 2020 Financial Results and Provides Corporate Update

MOUNTAIN VIEW, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) — – Initial Data from Phase 1 Trial of IGM-2323 in Relapsed/refractory Non-Hodgkin’s Lymphoma to be Presented at the 62nd American Society of Hematology Annual Meeting and Exposition in December – – First-in-Human Clinical Trial of IGM-8444 for the Treatment of Solid Cancers and Non-Hodgkin’s Lymphoma Initiated… Continue reading IGM Biosciences Announces Third Quarter 2020 Financial Results and Provides Corporate Update

IGM Biosciences to Present First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting

– Abstract Shows Encouraging Safety and Cytokine Release Data, Preservation of T cell Function and Repeatable T cell Activation – MOUNTAIN VIEW, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it expects the first clinical data… Continue reading IGM Biosciences to Present First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting